sb 202190 has been researched along with Memory Disorders in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Memory Disorders: Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, S | 1 |
| Zhou, G | 1 |
| Liu, H | 1 |
| Zhang, B | 1 |
| Li, J | 1 |
| Cui, R | 1 |
| Du, Y | 1 |
1 other study available for sb 202190 and Memory Disorders
| Article | Year |
|---|---|
Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia.
Topics: Animals; Apoptosis; Caspase 3; Dementia, Vascular; Disease Models, Animal; Gene Expression Regulatio | 2013 |